Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Emergent BioSolutions : to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021

10/18/2021 | 06:30am EST

GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financial outlook for full year 2021.

This conference call can be accessed live by telephone or by webcast:

eleconference Information:
Dial in number – toll-free: (855) 766-6521
Dial in number – toll: (262) 912-6157
Conference ID: 2937668

Webcast Information:
Visit https://edge.media-server.com/mmc/p/nitqgk48 for the live webcast.

A replay of the call can be accessed from the Emergent website.

Investor Contact:About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our website and follow us on LinkedIn, Twitter, and Instagram.

Robert G. Burrows
Vice President, Investor Relations
burrowsr@ebsi.com

Media Contact:
Matt Hartwig
Senior Director, Media Relations
hartwigm@ebsi.com


Primary Logo

Source: Emergent BioSolutions

2021 GlobeNewswire, Inc., source Press Releases

All news about EMERGENT BIOSOLUTIONS INC.
05:19pSpecial Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
RE
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600 Health Care
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 Health Care
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 - Biotechnology
CI
11/24Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
AQ
11/24Canada clears import of J&J COVID-19 vaccine doses made at Emergent plant
RE
11/23Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Gr..
PR
11/22SiTime to Join S&P MidCap 400, Pushing Emergent BioSolutions to S&P SmallCap 600 From N..
MT
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 689 M - -
Net income 2021 230 M - -
Net Debt 2021 371 M - -
P/E ratio 2021 10,0x
Yield 2021 -
Capitalization 2 298 M 2 298 M -
EV / Sales 2021 1,58x
EV / Sales 2022 1,42x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 42,72 $
Average target price 57,40 $
Spread / Average Target 34,4%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-51.31%2 347
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859